Hair Relaxer lawsuit update

Verified snapshot

The facts that anchor this dossier

A source-driven guide to MDL 3060 that separates the court's allegations from the Sister Study's observational findings, explains why Black women's exposure context matters, and avoids treating every straightener or cancer as interchangeable.

Federal proceeding

MDL 3060

Northern District of Illinois before Judge Mary M. Rowland.

Pending federal actions

11,779

JPML count as of August 3, 2026, against 16,199 historical actions in the same report.

Triggering research

2022 Sister Study

Frequent straightener use was associated with higher uterine-cancer incidence; the authors called for replication and chemical identification.

Other reported association

Ovarian cancer

A 2021 Sister Study analysis reported an association for frequent straightener/relaxer or pressing-product use, based on a limited number of cases.

Critical distinction

Association ≠ individual causation

Self-reported exposure, changing formulations, confounding, and product identification remain important.

Documented chronology

How the litigation reached this point

What MDL 3060 coordinates

The federal proceeding brings together lawsuits alleging that certain chemical hair relaxers or straighteners were defectively designed or inadequately warned about and caused cancers or other injuries. The JPML chose the Northern District of Illinois because common discovery would reach product development, regulatory history, and the scientific evidence. Defendants opposed centralization and dispute liability. The transfer order decided nothing about whether any product causes cancer.

The short-form complaint shows where the individualized layer begins. Filed plaintiffs incorporate a master complaint and then identify their own products, defendants, approximate use and diagnosis, and legal theories. A master pleading buys efficiency and leaves the proof requirements intact. The court's plaintiff fact sheet asks for sworn product-use and medical information, which is where brand, formulation, and dates of use come under scrutiny.

What the uterine-cancer study found

The 2022 Sister Study analysis followed 33,947 participants ages 35 to 74 who had a uterus at enrollment. Over an average 10.9 years, 378 uterine cancers were identified. Compared with never use in the previous year, ever use of straightening products carried a hazard ratio of 1.80. Frequent use, meaning more than four times in the previous year, carried a hazard ratio of 2.55. The same analysis found no association for dyes, bleach, highlights, or perms.

Those figures are relative estimates across a population. Several limits bound them: product use was self-reported at baseline, brands and ingredients were not comprehensively identified, and the number of cancers among frequent users was small. The authors called the finding the first epidemiologic evidence of its kind and asked for replication and for identification of the chemicals that might drive the association.

What the ovarian and breast analyses reported

A 2021 Sister Study analysis of 40,559 participants found no ovarian-cancer association for ever use of the examined hair products. Frequent use of straighteners, relaxers, or pressing products was associated with higher incidence, on an outcome count much smaller than the overall cohort, so precision and replication both matter here. A separate Sister Study analysis reported associations between straightener use and breast-cancer risk, again as observational evidence.

Each cancer in this litigation has its own biology and risk factors, and 'hair product' covers several distinct exposures. Relaxers that chemically alter curl pattern differ from keratin smoothing treatments that release formaldehyde when heated. FDA's formaldehyde guidance addresses the heat-activated smoothing products. Applying it to every relaxer named in MDL 3060 would overstate what the agency actually said.

Why exposure prevalence among Black women matters here

NIH reported that the uterine-cancer association did not statistically differ by race. The public-health impact could still be greater for Black women, because use is more prevalent and often begins younger. That is a statement about exposure, not a biological claim about race. The Sister Study cohort was racially diverse, though every participant had a sister with breast cancer, so the findings still need confirmation in other populations.

The social setting shapes exposure without saying anything about the people exposed. Hair texture norms, workplace expectations, and marketing all influence how often these products get used. Those facts explain why a product issue can land unequally, and they leave intact the dignity of people who made ordinary grooming choices with the information available at the time.

How to follow a docket this large

The current JPML report lists 11,779 pending actions against 16,199 historical actions, placing MDL 3060 among the largest active product-liability dockets. The gap between the two totals is the set of actions no longer pending. The report does not say why each one left the pending column: dismissals, transfers, and other case-specific events all move the number.

Official orders on expert evidence, dispositive motions, and trial selection are the developments worth watching. A rise in new filings reflects intake activity rather than strengthened science, and an old online deadline or dollar range should not be read as if the court issued it. Product containers, salon records, and treatment records help reconstruct an individual history, and this page stops well short of turning any of them into a determination of causation or value.

Reader questions

Frequently asked questions